DNLI PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

DNLI ▲ +9.50% at T+5d

SHORT call ✗ call lost -9.50% · α vs SPY -7.84% · entry $18.64 → $20.41

Next anchor: T+20d in 9d

Currently $21.66 · -16.20% from $18.64 entry (call sign-flipped)

Entry anchored
May 21, 2026
via day open

T+1d

+3.97%

call -3.97% · α -3.38%

$19.38

settled 22d ago

T+5d

+9.50%

call -9.50% · α -7.84%

$20.41

settled 15d ago

T+20d

—

call — · α —

—

in 9d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 in idiopathic Parkinson's disease will be discontinued, while the Phase 2a BEACON study in LRRK2 variant carriers continues. This is a significant pipeline setback for Denali.

Actionable Insight

Expect a sharp negative stock reaction on the open. Monitor for analyst downgrades and any updates on the BEACON study. The continued BEACON program provides a small offset, but the idiopathic PD market was the primary opportunity.

Key Facts

Phase 2b LUMA study (n=648) did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
Secondary endpoints also showed no benefit for BIIB122 versus placebo.
Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
Denali will continue the Phase 2a BEACON study in LRRK2 pathogenic variant carriers, with data expected in first half of 2027.
Exploratory biomarkers showed >90% peripheral LRRK2 kinase inhibition and up to ~30% reduction in CSF pRab10.

Financial Impact

Significant devaluation of the Parkinson's disease pipeline; BIIB122 was a key partnered asset with Biogen. The discontinuation removes a major value driver for Denali.

pipeline valuepartnership value

Risk Factors

The BEACON study may also fail, eliminating the entire LRRK2 program.
Partnership with Biogen may be reevaluated, impacting future collaboration revenues.
Potential need for additional capital if pipeline value erodes.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

92% bullish (25 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3299824

6 reports for DNLI

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for DNLI — sortable, filterable
	Type				Now
Jun 11, 2026 2d ago	Institutional Cluster MIXED ★ 4/10	$21.01 awaiting T+5	awaiting T+5	—	$21.66 (+3.09%)
May 21, 2026 22d ago	Press Release BEARISH ★ 7/10	$18.64 $20.41	▼ −9.50%	▼ −7.84%	$21.66 (−16.20%)
May 7, 2026 5w ago	Press Release BULLISH ★ 7/10	$19.62 $19.39	▼ −1.17%	▼ −2.64%	$21.66 (+10.40%)
Apr 3, 2026 10w ago	8-K NEUTRAL ★ 5/10	$19.38 $19.42	▲ +0.21%	▼ −3.93%	$21.66 (+11.76%)
Apr 3, 2026 10w ago	Press Release MIXED ★ 6/10	$19.38 $19.42	▲ +0.21%	▼ −3.93%	$21.66 (+11.76%)
Mar 25, 2026 11w ago	Press Release BULLISH ★ 9/10	$22.47 $19.68	▼ −12.42%	▼ −12.17%	$21.66 (−3.60%)

US Market Status

Market Closed — Opens Mon (47h 38m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access